In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.
A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma-bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.
Zauli
Giorgio
G
Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. giorgio.zauli@unife.it
Corallini
Federica
F
Zorzet
Sonia
S
Grill
Vittorio
V
Marzari
Roberto
R
Secchiero
Paola
P
D000818:Animals; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007274:Injections, Intraperitoneal; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology*; D057127:Single-Chain Antibodies / Q000008:administration & dosage*; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays
D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D057127:Single-Chain Antibodies; C505639:TNFRSF10B protein, human